Introduction {#section5-1178633720909798}
============

*Escherichia coli* and *Klebsiella* species are the most common causative pathogens for most of the infections, especially in countries with poor health care system.^[@bibr1-1178633720909798]^ *E. coli* is a normal flora of human and animal gut but can also be found in water, soil, and vegetation.^[@bibr2-1178633720909798]^ *Klebsiella* species are considered as major opportunistic pathogens that can cause infections mostly in children. *Klebsiella pneumoniae* is an important cause of human infections among all *Klebsiella* species, followed by *Klebsiella oxytoca, Klebsiella ozaenae*, and *Klebsiella rhinoscleromatis.* Several common bacterial infections such as gastroenteritis, urinary tract infection (UTI), septicemia, and neonatal meningitis are mainly caused by *E. coli* and *Klebsiella* spp in children.^[@bibr3-1178633720909798],[@bibr4-1178633720909798]^

Commonly used antimicrobial agents against these pathogens are tetracycline, β-lactams, fluoroquinolones, aminoglycosides, and cotrimoxazole. However, antimicrobial resistance (AMR) among Enterobacteriaceae has increased dramatically in recent years, limiting the therapeutic options. Isolates that are not susceptible to at least 3 or more groups of antimicrobials are known as multidrug resistant (MDR) organisms.^[@bibr5-1178633720909798]^

Extended-spectrum β-lactamases (ESBLs) are class A β-lactamases, a rapidly evolving group of β-lactamases with the ability to hydrolyze and cause resistance to the oxy-imino cephalosporins (cefotaxime, ceftazidime, ceftriaxone, cefuroxime, and cefepime) and monobactams (aztreonam).^[@bibr6-1178633720909798]^ ESBL-producing *E. coli* and *K. pneumoniae* are the predominant cause of childhood infections and present significant challenges^[@bibr7-1178633720909798]^ such as development of adverse outcomes,^[@bibr8-1178633720909798]^ treatment failure due to multidrug resistance, and high morbidity and mortality.^[@bibr9-1178633720909798]^ Empirical and symptomatic (without a diagnosis) use of antibiotics in resource poor settings is responsible for higher incidence of antibiotic resistance among bacteria.^[@bibr10-1178633720909798]^

Several studies in the past have investigated the prevalence of ESBL organisms among inpatients, mostly focused in adult patients.^[@bibr11-1178633720909798][@bibr12-1178633720909798]-[@bibr13-1178633720909798]^ Studies have shown the varying prevalence of ESBL organisms, for instance, the prevalence was 27.7% in Pokhara,^[@bibr11-1178633720909798]^ 18% in Kathmandu,^[@bibr14-1178633720909798]^ 43% in pediatric hospital in Kathmandu.^[@bibr15-1178633720909798]^ Another study reported 35.9% ESBL in *E coil* isolates among outpatients at tertiary care hospital in Kathmandu.^[@bibr12-1178633720909798]^ However, similar study from Lalitpur district reported 6.8% ESBL-producing isolates.^[@bibr13-1178633720909798]^ Studies have shown the wide range in the prevalence of ESBLs (10%-43%) in different hospitals/settings from various samples.

Although it is deemed to be essential to have a routine diagnosis and monitoring of ESBL-producing clinical isolates in clinical laboratories, ESBL screening as a routine test has not yet been practiced in Nepal.^[@bibr16-1178633720909798]^ In addition, very few studies have reported on ESBL-producing clinical isolates from pediatric patients in Nepal. Only 1 study in the past has reported ESBLs (prevalence: 38.9%) from urine samples in pediatric patients from a tertiary teaching hospital in Kathmandu.^[@bibr17-1178633720909798]^ Expanding and building on the previous research, this study focused to isolate both *E. coli* and *Klebsiella* spp from wider and larger number of clinical specimens from pediatric patients. The main objectives of this study were to explore the prevalence of ESBL-producing organisms, including the resistance types among pediatric patients attending a tertiary care pediatric hospital at Kathmandu.

Methods {#section6-1178633720909798}
=======

Study design, area, and sample population {#section7-1178633720909798}
-----------------------------------------

This was a cross-sectional study conducted at International Friendship Children's Hospital, Maharajgunj, Kathmandu, Nepal, during August 2017 to January 2018. The study population comprised children below 15 years attending the hospital for treatment.

The specimens were collected adhering to a standard protocol from pediatric patients below 15 years of age. Children who attended the hospital for treatment and provided assent (from parents) or consent for the study were included in the study. Children who had chronic diseases such as leukemia, malnutrition, and neuropsychiatric disorders based on the diagnosis made by clinicians, including if they were initiated with the antibiotic treatment after the admission, were excluded.

A total of 1443 different samples that included urine (n = 1050), pus (n = 50), wound swabs (n = 40), endotracheal tip (n = 83), catheter tip (n = 40), and blood (n = 140) were collected and processed by standard microbiological methods.^[@bibr18-1178633720909798]^

Sample collection and transport {#section8-1178633720909798}
-------------------------------

Special measures were taken to collect the urine samples from children who were not able to use toilet on their own. An adhesive, sealed, sterile collection bag was placed underneath the genitalia to collect urine sample. Toilet-trained children were requested to collect mid-stream urine assisted by their parents in a sterile, dry, wide-necked, and leak-proof container. In either condition, genitalia were cleansed with alcohol swab to reduce contamination.

In the case of infected wounds, in addition to wound swab, pus was aspirated in syringe by trained medical personnel. In case pus was not discharging, cotton swab was gently rolled over the surface of the wound approximately 5 times, focusing on areas where there was evidence of pus or inflamed tissue. Two swabs were taken from each patient, one for culture and another for direct gram staining.

About 2 mL of blood from children was withdrawn and dispensed into sterile screw capped culture bottles containing BHI (brain heart infusion) broth. Specimens were collected from other sources such as endotracheal and catheter tips by trained medical personnel. The collected samples were labeled properly and were immediately delivered to a laboratory for further processing. When immediate delivery was not possible, the specimens were refrigerated at 4°C to 6°C.^[@bibr19-1178633720909798]^

Laboratory examinations of samples {#section9-1178633720909798}
----------------------------------

### Culture {#section10-1178633720909798}

For processing of each sample, microbiological protocols were followed according to standard microbiological guidelines.^[@bibr18-1178633720909798],[@bibr20-1178633720909798]^

1.  Urine sample: Using a sterile calibrated loop, urine sample was inoculated on MacConkey agar (MA) and blood agar (BA), and then incubated aerobically at 37°C for 24 hours. Colony count was made, and positive result was considered for plates showing more than or equal to 10^5^ colony forming units (CFU)/mL of urine based on Kass, Marple, and Sanford criteria.^[@bibr20-1178633720909798]^

2.  Blood sample: Blood sample was incubated on BHI broth for 7 days at 37°C. Bottles showing turbidity during the period were subcultured aerobically in MA and BA at 37°C for 24 to 48 hours.

3.  Pus, wound swab specimens were inoculated into MA and BA plate sand incubated at 37°C overnight.

4.  Other specimens: Endotracheal and catheter tips were first incubated on BHI broth at 37°C for 24 hours and subcultured on MA and BA plates and incubated at 37°C overnight.

### Identification of E. coli and Klebsiella spp {#section11-1178633720909798}

Presumptive identification of *E coli* and *Klebsiella* spp was done on the basis of colony color and Gram staining morphology. Then, obtained pure cultures of isolates were assessed for various biochemical tests (indole, methyl red, Voges-Proskauer, citrate, triple sugar iron agar, oxidative/fermentative, urease test for confirmation).^[@bibr18-1178633720909798],[@bibr20-1178633720909798]^

Antibiotic susceptibility testing {#section12-1178633720909798}
---------------------------------

All identified isolates of *E coli* and *Klebsiella* spp were treated for susceptibility testing against ampicillin (10 μg), gentamicin (10 μg), amikacin (30 μg), aztreonam (30 μg), cefoxitin (30 μg), ceftazidime (30 μg), cefotaxime (30 μg), ceftriaxone (30 μg) ciprofloxacin (5 μg), imipenem (10 μg), piperacillin/tazobactam (100/10 μg), nitrofurantoin (300 µg), and cefepime (30 μg) (HiMedia India Pvt. Ltd, Bengaluru, India) following Kirby-Bauer method on Mueller-Hinton Agar (HiMedia India Pvt. Ltd). Results were interpreted based on the Clinical and Laboratory Standards Institute (CLSI) 2016 guidelines.^[@bibr21-1178633720909798]^ Those isolates which were not susceptible (either resistant or intermediate) to 3 or more antibiotics classes were considered as MDR.^[@bibr5-1178633720909798]^

### Screening and confirmation of ESBL producers {#section13-1178633720909798}

Bacterial isolates exhibiting reduced susceptibility to ceftazidime (30 μg), cefotaxime (30 µg), ceftazidime (30 µg), and aztreonam (30 μg) were considered as potential ESBL producers. The ESBL production was further phenotypically confirmed by combination disk method as described by CLSI 2014. The disk used was cefotaxime and ceftazidime alone and cefotaxime and ceftazidime in combination with clavulanic acid. A ⩾5 mm increase in growth inhibition zone for any antimicrobial associated with clavulanic acid in comparison with the inhibition zone of antibiotic tested alone confirmed ESBL production.^[@bibr21-1178633720909798]^

Quality control {#section14-1178633720909798}
---------------

Each batch of media and reagents was subjected to sterility and performance testing. During antibiotic susceptibility test, quality control was done using the control strains of *E coli* ATCC 25922.

Data management and statistical analysis {#section15-1178633720909798}
----------------------------------------

Data were entered and analyzed by using IBM SPSS Statistics for Windows, Version 21.0 (IBM Corp, Armonk, NY, USA). Descriptive and inferential statistics were analyzed.

Results {#section16-1178633720909798}
-------

### Prevalence of bacterial isolates {#section17-1178633720909798}

A total of 1443 different clinical specimens were processed during the study, of which 299 (20.7%) samples showed bacterial growth. Of the 299 isolates, 79 (26.4%), 18 (6.0%), and 6 (2%) were identified as *E. coli, K. pneumonia*, and *K. oxytoca*, respectively. *E. coli* was predominant bacteria isolated from urine samples (86.0%; 68/79), followed by pus/wound pus samples (8.8%; 7/79). *K. pneumoniae* (77.8%; 14/18) and *K. oxytoca* (83.3%; 5/6) were mostly isolated from urine samples ([Table 1](#table1-1178633720909798){ref-type="table"}).

###### 

Distribution of bacterial isolates in various clinical specimens of children.

![](10.1177_1178633720909798-table1)

  Samples            Total (%)     Bacterial isolates               
  ------------------ ------------- -------------------- ----------- ----------
  Urine              87 (84.5)     68 (86.0)            14 (77.8)   5 (83.3)
  Pus/wound pus      11 (10.7)     7 (8.8)              3 (16.7)    1 (16.7)
  Endotracheal tip   2 (1.9)       2 (2.5)              0 (0.0)     0 (0.0)
  Catheter tip       2 (1.9)       1 (1.3)              1 (5.5)     0 (0.0)
  Blood              1 (1)         1 (1.3)              0 (0.0)     0 (0.0)
  Total              103 (100.0)   79 (76.7)            18 (17.5)   6 (5.8)

Antibiotic susceptibility pattern of bacterial isolates {#section18-1178633720909798}
-------------------------------------------------------

Among 103 bacterial isolates, 90.3% (n = 93) were found to be susceptible to imipenem, followed by piperacillin/tazobactam (88.3%; n = 91), nitrofurantoin (85.5%; n = 88), and amikacin (82.5%; n = 85). Most *E. coli* isolates (92.4%; 73/79) were found to be susceptible to imipenem, followed by nitrofurantoin (91.2%; 72/79). Similarly, 88.9% (16/18) of *K. pneumoniae* were found to be susceptible to amikacin. *K. oxytoca* were found to be 100% (6/6) susceptible to gentamicin, piperacillin/tazobactam, and imipenem ([Table 2](#table2-1178633720909798){ref-type="table"}).

###### 

Antibiotic susceptibility pattern of bacterial isolates (*Escherichia coli* and *Klebsiella* spp).

![](10.1177_1178633720909798-table2)

  Antibiotics                Antibiotic susceptibility pattern of *E. coli* and *Klebsiella* spp                                                     
  -------------------------- --------------------------------------------------------------------- ----------- ------------- ----------- ----------- ----------
  Gentamicin                 66 (83.5)                                                             13 (16.5)   12 (66.7)     6 (33.3)    6 (100.0)   0 (0.0)
  Amikacin                   64 (81.0)                                                             15 (19.0)   16 (88.9)     2 (11.1)    5 (83.3)    1 (16.7)
  Ciprofloxacin              40 (50.6)                                                             39 (49.4)   6 (33.3)      12 (66.7)   3 (50.0)    3 (50.0)
  Ampicillin                 22 (27.8)                                                             57 (72.2)   1 (5.6)       17 (94.4)   2 (33.3)    4 (66.7)
  Piperacillin\\tazobactam   70 (88.61)                                                            9 (11.9)    15 (83.3)     3 (16.7)    6 (100.0)   0 (0.0)
  Imipenem                   73 (92.4)                                                             6 (7.6)     14 (77.8)     4 (22.2)    6 (100.0)   0 (0.0)
  Aztreonam                  60 (76.0)                                                             19 (24.0)   11 (61.1)     7 (38.9)    5 (83.3)    1 (16.7)
  Cefotaxime                 35 (44.3)                                                             44 (55.7)   3 (16.7)      15 (83.3)   4 (66.7)    2 (33.3)
  Ceftriaxone                37 (46.8)                                                             42 (53.2)   7 (38.9)      11 (61.1)   4 (66.7)    2 (33.3)
  Ceftazidime                37 (46.8)                                                             42 (53.2)   7 (38.9)      11 (61.1)   4 (66.7)    2 (33.3)
  Cefepime                   42 (53.2)                                                             37 (46.8)   11 (61.1)     7 (38.9)    4 (66.7)    2 (33.3)
  Cefoxitin                  53 (67.1)                                                             26 (32.9)   7 (38.9)      11 (61.1)   5 (83.3)    1 (16.7)
  Nitrofurantoin             72 (91.2)                                                             7 (8.8)     12 (66.7.8)   6 (33.3)    4 (66.7)    2 (33.3)

MDR profile in bacterial isolate {#section19-1178633720909798}
--------------------------------

Among the total of 103 bacterial isolates, 62.1% (64/103) were found to be MDR; the highest MDR strains were detected in *K. pneumoniae* (88.9%; 16/18), followed by *E. coli* (57%; 44/79) and *K. oxytoca* (50%; 3/6) ([Figure 1](#fig1-1178633720909798){ref-type="fig"}).

![MDR profile in bacterial isolates.\
MDR indicates multidrug resistant.](10.1177_1178633720909798-fig1){#fig1-1178633720909798}

ESBL production among E coli and Klebsiella spp {#section20-1178633720909798}
-----------------------------------------------

Among 103 *E. coli* and *Klebsiella* isolates, 28.2% (29/103) were confirmed as ESBL producers by combination disk diffusion method. The highest percentage of ESBL production was found among *K. pneumoniae* (33.3%; 6/18), followed by *E. coli* (27.9%; 22/79) and *K. oxytoca* (16.7%; 1/6) ([Table 3](#table3-1178633720909798){ref-type="table"}).

###### 

ESBL production profile among *Escherichia coli* and *Klebsiella* spp.

![](10.1177_1178633720909798-table3)

  Organisms                 No. of isolates   ESBL producer
  ------------------------- ----------------- ---------------
  *E. coli*                 79                22 (27.8)
  *Klebsiella pneumoniae*   18                6 (33.3)
  *Klebsiella oxytoca*      6                 1 (16.7)
  Total                     103               29 (28.2)

Abbreviation: ESBL, extended spectrum β-lactamase.

### Distribution of ESBL producers according to different age of patient {#section21-1178633720909798}

Among the 103 isolates, 77.7% (n = 80) were isolated from children ⩽5 years age, followed by 6 to 10 years age group children (15.5%; n = 16). Of 103 bacterial isolates, 28.1% (n = 29) were ESBL producers and the most (82.8%; n = 24) were isolated from children ⩽5 years of age. There was no association between ESBL producers and age of patients (*P* \< .05) ([Table 4](#table4-1178633720909798){ref-type="table"}).

###### 

Distribution of ESBL according to sex and age of children.

![](10.1177_1178633720909798-table4)

  Age groups, y   No. of isolates (%)   ESBL production   *P*-value
  --------------- --------------------- ----------------- ------------------------------------------------------------
  ⩽5              80 (77.7)             24 (82.8)         
  6-10            16 (15.5)             4 (13.8)          .837[\*](#table-fn3-1178633720909798){ref-type="table-fn"}
  11-15           7 (6.8)               1 (3.4)           
  Total           103 (100.0)           29 (28.1)         

Abbreviation: ESBL, extended spectrum β-lactamase.

χ^2^ test.

### Distribution of ESBL producers in different wards of hospitals {#section22-1178633720909798}

Of 29 isolates of ESBL producers, 51.7% (n = 15) were from inpatients, whereas 48.3% (n = 14) were from outpatient department. There was no significant association between ESBL production and type of the patients (*P* \> .05) ([Table 5](#table5-1178633720909798){ref-type="table"}).

###### 

Distribution of ESBL producers in different wards of hospitals.

![](10.1177_1178633720909798-table5)

  Wards             No. of isolates (%)   ESBL producer bacterial isolates (%)   *P*-value
  ----------------- --------------------- -------------------------------------- ------------------------------------------------------------
  Outpatients                                                                    
   OPD              52 (50.5)             14 (48.3)                              
  Inpatients                                                                     .737[\*](#table-fn5-1178633720909798){ref-type="table-fn"}
   ICU              13 (12.6)             5 (17.2)                               
   Other than ICU   38 (36.9)             10 (34.5)                              
  Total             103 (100.0)           29 (28.1)                              

Abbreviations: ESBL, extended spectrum β-lactamase; ICU, intensive care unit; OPD, outpatient department.

χ^2^ test.

### Antibiotic susceptible pattern of ESBL producers {#section23-1178633720909798}

All of ESBL producers' isolates were found to be resistant toward cefotaxime, ceftriaxone, ceftazidime, and ampicillin. Most ESBL producers were found to be susceptible toward imipenem (89.7%; 26/29), nitrofurantoin (82.8%; 24/29), piperacillin/tazobactam (79.3%; 23/29), and amikacin (72.4%; 21/29) ([Figure 2](#fig2-1178633720909798){ref-type="fig"}).

![Antibiotic susceptibility pattern of ESBL producers.\
ESBL indicates extended-spectrum β-lactamase.](10.1177_1178633720909798-fig2){#fig2-1178633720909798}

Discussion {#section24-1178633720909798}
==========

Overall findings {#section25-1178633720909798}
----------------

This study found the high prevalence (\>60%) of MDR bacteria in clinical specimens isolated from the tertiary care hospital of children in Kathmandu valley. Among MDR isolates, half of the isolates were ESBL producers. Most ESBL-producing isolates were found to be resistant toward cefotaxime, ceftriaxone, ceftazidime, and ampicillin. Similar findings were reported in previous studies in different clinical settings of Nepal.^[@bibr12-1178633720909798],[@bibr17-1178633720909798],[@bibr22-1178633720909798],[@bibr23-1178633720909798]^

Most isolates (\>80%) in this study were found susceptible to imipenem, piperacillin/tazobactam, and amikacin. The high efficacy of amikacin and imipenem against *E. coli* and *Klebsiella* was also reported from studies conducted in Chitwan^[@bibr24-1178633720909798]^ and Lumbini,^[@bibr25-1178633720909798]^ Nepal. The findings were also in line with a study from Manipal Teaching Hospital, Pokhara.^[@bibr11-1178633720909798]^

Most isolates (77.5%) were resistant to ampicillin and more than half of the cephalosporin group of antibiotics. Similar findings were observed in a tertiary hospital in Pokhara, Nepal.^[@bibr11-1178633720909798]^ This type of resistance could be due to the production of several β-lactamase enzymes. As ampicillin is the first-line β-lactam drug for Enterobacteriaceae, it can be easily hydrolyzed by β-lactamase enzymes. Resistance to fluoroquinolones is due to mutation at the target site, ie, *gyrA* (gyrase subunit gene) and *parC* (topoisomerase subunit gene) and efflux.^[@bibr26-1178633720909798]^

The AMR, including MDR, is a global problem, and its burden varies between the regions; however, low- and middle-income countries share a disproportionate burden due to multitude of factors embedded in the characteristics of the health system, policy, and the practice.^[@bibr27-1178633720909798]^ Moreover, MDR pathogens are more common in hospital settings and are mostly of nosocomial origin which is often difficult to treat.^[@bibr28-1178633720909798]^ MDR pose a major threat in the management of uropathogens.^[@bibr29-1178633720909798][@bibr30-1178633720909798]-[@bibr31-1178633720909798]^ More than two-thirds of the isolates in this study were MDR, mostly being *E. coli, K. pneumoniae*, and *K. oxytoca*. A high prevalence of MDR strains have been reported consistently from past studies from within Kathmandu^[@bibr10-1178633720909798],[@bibr12-1178633720909798],[@bibr17-1178633720909798],[@bibr28-1178633720909798]^ and outside.^[@bibr8-1178633720909798],[@bibr14-1178633720909798],[@bibr16-1178633720909798]^ Bacterial resistance to β-lactam antibiotics has risen dramatically, with significant contribution by ESBL.^[@bibr32-1178633720909798]^

*E. coli* and *K. pneumoniae* are major ESBL producers posing serious threat to the treatment regimen.^[@bibr33-1178633720909798]^ ESBL enzymes are becoming increasingly expressed by many strains of pathogenic bacteria presenting diagnostic challenges to the clinical microbiology laboratories.^[@bibr34-1178633720909798]^ The highest bacterial isolates were found in children less than 5 years age, including the prevalence of ESBL organisms which was above 80%. The reason for this may be due to the immunological status of the children below 5 years of age who are more vulnerable to infections. The higher prevalence of bacterial growth in inpatients may have been added by nosocomial infections. Nosocomial infections are associated with prolonged hospital stay, intensive care unit admission, extensive use of invasive medical devices, and overconsumption of antibiotic among inpatients.^[@bibr35-1178633720909798],[@bibr36-1178633720909798]^

Most ESBL organisms were susceptible to imipenem, piperacillin/tazobactam, amikacin, and nitrofurantoin. However, ESBL producers were resistant to ampicillin and cephalosporin group of antibiotics. These findings are consistent with similar studies reported from Nepal.^[@bibr11-1178633720909798],[@bibr33-1178633720909798],[@bibr37-1178633720909798][@bibr38-1178633720909798]-[@bibr39-1178633720909798]^ The high proportion of resistance to third-generation cephalosporins reported for *E. coli* and *K. pneumoniae* means that treatment of severe infections likely to be caused by these bacteria in many settings must rely on carbapenems, the last resort to treat severe community- and hospital-acquired infections.^[@bibr40-1178633720909798]^

Increasing spectrum of ESBL drug-resistant bacterial isolates can cause major problems for physicians in choosing from the available therapeutic options, if these organisms are not routinely isolated. Reporting of ESBL-producing isolates from clinical samples is thus critical for the clinicians to select appropriate antibiotics for the treatment, including to take proper precaution to prevent the spread of these resistant organisms to other patients.

Strengths and limitations {#section26-1178633720909798}
-------------------------

This study will be a useful reference for future studies to explore and expand on the wider prevalence of ESBL organisms in clinical and nonclinical settings. As our study was based on phenotypic detection of AMR and ESBL production that excluded identification and characterization of wide sorts of lactamases and pathogenic strains, genotypic characterization is recommended in future studies.

Implications for AMR and its control {#section27-1178633720909798}
------------------------------------

This study has identified one of the major determinants of burgeoning AMR in Nepal. All antibiotics are available over the counter (OTC) in Nepal without medical prescriptions, and this is a major challenge as it contributes to antibiotic pressure and development of resistance.^[@bibr27-1178633720909798],[@bibr41-1178633720909798]^ The availability of OTC antibiotics and its consumption before arriving to hospitals may also confound the clinical presentation, including general culture and sensitivity tests.^[@bibr27-1178633720909798]^ Thus, cautious evaluation of preceding treatment history, combined with strong suspicion for ESBL and MDR and its diagnosis, may inform the appropriate treatment.^[@bibr11-1178633720909798],[@bibr16-1178633720909798]^ The findings in this study warrant a relevant stakeholder's engagement to strengthen the health policy to rationalize the use of antibiotics, including promoting diagnostic-based antibiotic prescriptions.^[@bibr42-1178633720909798]^ Specifically, in pediatric patients with UTIs, it is critical to establish the diagnosis of ESBL organisms before initiating the antibiotic treatment.

Conclusion {#section28-1178633720909798}
==========

A high prevalence of MDR ESBL organisms was found among pediatric patients in this study. Identification of ESBL producers in routine treatment of infectious diseases in pediatric patients can reduce unnecessary and inappropriate antimicrobial use. Hospitals treating infectious diseases can benefit by integrating antimicrobial stewardship programs to combat the emergence of AMR and ESBLs.
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